Look for any podcast host, guest or anyone
Showing episodes and shows of

Xiuning Le

Shows

The Oncology Insights Podcast
The Oncology Insights PodcastDr. Xiuning Le: Precision Oncology in Lung Cancer | Ep. 12In this episode of The Oncology Insights Podcast, I speak with Dr. Xiuning Le, Associate Professor and Section Chief at The University of Texas MD Anderson Cancer Center, about the evolution of precision medicine in lung cancer. We discuss actionable mutations, targeted therapies, immunotherapy, early detection strategies, brain metastases, and emerging innovations shaping the future of oncology care. Listen now on all major platforms!"Targeted therapies are developed by understanding which oncogenic pathways drive tumor growth and identifying methods to overcome treatment resistance."Meet the guest: Dr. Xiuning Le...
2026-06-1533 minAdis Journal Podcasts
Adis Journal PodcastsHER2-mutant Non-small Cell Lung Cancer Podcast: Knowledge Is Power (Episode 1) In the first episode of our podcast series, Vivek Subbiah from the Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA, Martin Dietrich from the US Oncology Network and Cancer Care Centers of Brevard, Orlando, FL, USA, and Xiuning Le from the University of Texas MD Anderson Cancer Center, Houston, TX, USA introduce the emerging landscape of HER2-mutant non-small cell lung cancer (NSCLC), highlighting its place within the broader context of lung cancer. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted...
2026-05-1318 minOncLive® On Air
OncLive® On AirShow Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities Highlights from the PER® CME activity "Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Christine M. Lovly, MD, PhD, FASCO; Lyudmila Bazhenova, MD; Hossein Borghaei, DO, MS; and Xiuning Le, MD, PhD, discuss how to sequence systemic therapy based on the molecular profile of non–small cell lung cancer that has progressed on a first-line EGFR-directed tyrosine kinase inhibitor, including discussion on the us...
2026-03-1028 minAudio Journal of Oncology Podcast
Audio Journal of Oncology PodcastXiuning Le MD PhD; ESMO 2025: Sevabertinib Success for Patients with HER2-Mutated Non-Small Cell Lung Cancer in SOHO-01 StudyA new anti cancer drug sevabertinib, that targets mutated HER2, has proved effective in the SOHO-01 study among patients wiith HER2 mutated non small cell lung cancer. It has now been reported in the
2025-10-3100 minLung Cancer Considered
Lung Cancer ConsideredIASLC Lung Cancer Considered: ESMO 2025 HighlightsThis episode of Lung Cancer Considered covers highlights from the 2025 ESMO Annual Meeting held October 17th to the 21st in Berlin, Germany. Guests are: Dr. Xiuning Le from MD Anderson Cancer Center in Houston, Texas. Dr. Pedro Rocha from Vall d’Hebron University Hospital in Barcelona, Spain. Dr. Riyaz Shah, a consultant medical oncologist at the Kent Oncology Centre in the United Kingdom.
2025-10-2837 minOncology On The Go
Oncology On The GoWhat Were the Key Presentations at ESMO 2025? Oncology Experts DiscussAs part of the European Society for Medical Oncology (ESMO) Congress 2025, CancerNetwork® spoke with a variety of experts about key takeaways from different late-breaking abstracts, oral presentations, and other sessions focused on potential advancements across cancer care. Presenting investigators highlighted updated results from clinical trials evaluating novel therapeutic strategies across different cancer populations, including breast cancer and lung cancer. Phase 3 VIKTORIA-1 TrialSara A. Hurvitz, MD, FACP, the Smith Family Endowed Chair in Women’s Health and senior vice president and director of the Clinical Research Division at the Fred Hutch Cancer Center, and tumor chair in b...
2025-10-2711 minOncLive® On Air
OncLive® On AirIvonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhDIn today’s episode, supported by Summit Therapeutics, we had the pleasure of speaking with Xiuning Le, MD, PhD, about the use of ivonescimab (SMT112) in patients with PD-L1–positive non–small cell lung cancer (NSCLC). Dr Le is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center in Houston.The phase 3 HARMONi-2 trial (NCT05499390) investigated ivonescimab vs pembrolizumab (Keytruda) in patients with locally advanced or metastatic, PD-L1–positive NSCLC without sensitizing EGFR mutations or ALK translocations. At the preplann...
2025-03-2411 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-11-1413 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-11-1413 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-11-1416 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-11-1416 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-11-1413 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-11-1413 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-11-1416 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-11-1416 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-10-1614 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-10-1614 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-10-1615 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-10-1615 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-10-1614 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-10-1614 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-10-1615 mintouchPODCAST
touchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...
2024-10-1615 minLung Cancer Considered
Lung Cancer ConsideredLive From WCLC 2024: Monday HighlightsIn this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Narjust Florez discusses daily highlights from the conference. Dr. Xiuning Le reports updated results of BAY 292708, and Dr. Gerrina Ruiter summarizes the Beamion LUNG-1 study, both of which evaluate the efficacy of therapies for patients with HER2-Mutant NSCLC. Dr. Fiona Hegi-Johnson adds her perspective as a discussant of the POLESTAR trial evaluating EGFR therapy after chemoradiation in stage III unresectable NSCLC. Guests: Dr. Fiona Hegi-Johnson Radiation Oncologist at the Peter MacCallum Cancer Centre Senior Research Fellow at the University of Melbourne Dr. Xiuning Le, M.D., Ph.D. ...
2024-09-1037 minLung Cancer Considered
Lung Cancer ConsideredLCC In MandarinAs part of IALC's ongoing series of podcasts in world languages, this podcast brings together four of the leading Chinese lung cancer experts who discuss current research and clinical issues, in Mandarin. Host: Chunxia Su, M.D., PhD, Professor of Oncology, Doctoral Supervisor, School of Medicine, Tongji University Guest: Xiuning Le, MD, Department of Thoracic-Head & Neck Med Oncology, Division of Cancer Medicine, MD Anderson Guest: Jianming Ying, Professor & Director Department of Pathology National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences Guest: Professor Li Zhang, Director of the Department of Internal Medicine, Doctoral Supervisor, Second Class Professor, and Chief...
2024-08-1640 minOncology Times - OncTimes Talk
Oncology Times - OncTimes TalkDoublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC ProgressionThe multicenter RAMOSE randomized clinical trial has found that doublet growth factor tyrosine kinase inhibitor therapy, when compared with standard osimertinib monotherapy, achieved a statistically significant improvement in progression-free survival in patients whose advanced non-small cell lung cancers were driven by mutated epidermal growth factor receptor. First author Xiuning Le, MD, PhD, Associate Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center, has been discussing her group’s findings with Peter Goodwin, an OncTimesTalk correspondent.
2024-03-0416 minOncTimes Talk
OncTimes TalkDoublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC ProgressionThe multicenter RAMOSE randomized clinical trial has found that doublet growth factor tyrosine kinase inhibitor therapy, when compared with standard osimertinib monotherapy, achieved a statistically significant improvement in progression-free survival in patients whose advanced non-small cell lung cancers were driven by mutated epidermal growth factor receptor.   First author Xiuning Le, MD, PhD, Associate Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center, has been discussing her group's findings with Peter Goodwin, an OncTimesTalk correspondent.
2024-03-0416 minOncology Times - OncTimes Talk
Oncology Times - OncTimes TalkDouble TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung CancerAmong patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC international conference on Molecular Targets and Cancer Therapeutics. Presenting author Xiuning Le, MD, PhD, from the MD Anderson Cancer Center in Houston, Texas, has been talking with OncTimes Talk’s Peter Goodwin about her group’s study in which osimertinib was combined with the MET-tyrosine kinase inhibitor tepotinib in pat...
2023-11-1615 minAdis Journal Podcasts
Adis Journal PodcastsEGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A PodcastIn this podcast, Xiuning Le from the University of Texas MD Anderson Cancer Center, Houston, TX, Eric Nadler from the Baylor University Medical Center, Dallas, TX, Daniel Costa from the Beth Israel Deaconess Medical Center, Harvard Medical School,... In this podcast, Xiuning Le from the University of Texas MD Anderson Cancer Center, Houston, TX, Eric Nadler from the Baylor University Medical Center, Dallas, TX, Daniel Costa from the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, and John Heymach from the University of Texas MD Anderson Cancer Center, Houston, TX discuss the use of EGFR tyrosine kinase...
2023-10-0441 min